Physician profile
Gary Tollin
NPI 1982107587
$4,002.03
in general payments reported to CMS, 2019-2025
23 companies · $929 in 2025
The $929 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.06 · 2022: $646 · 2023: $990 · 2024: $1,421 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,339.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $739.11 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $733.33 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $640.76 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $598.61 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $323.00 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $244.57 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $131.03 | 2022-2025 | |
| Exact Sciences Corporation | $101.88 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $82.93 | 2021-2024 | Xarelto |
| Abbvie INC. | $80.88 | 2023-2025 | Ubrelvy, Synthroid |
| Esperion Therapeutics, INC. | $57.30 | 2023-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $41.59 | 2024 | Gemtesa |
| Eisai INC. | $36.82 | 2024-2025 | |
| Renalytix Ai, INC. | $35.20 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Abbott Laboratories | $24.21 | 2024 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.32 | 2025 | Rexulti |
| Hikma Pharmaceuticals USA | $18.48 | 2023 | Ryaltris |
| Phathom Pharmaceuticals, INC. | $17.88 | 2024 | Voquezna |
| Corcept Therapeutics | $17.61 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $15.06 | 2022 | |
| Heartflow, INC. | $14.40 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.30 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Tollin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.